

## **Carelon Medical Benefits Management Clinical Appropriateness Guidelines and CPT code list update**

Effective for dates of service on and after June 1, 2023, the following codes will require prior authorization (PA) through Carelon Medical Benefits Management.

As a reminder, ordering and servicing providers may submit prior authorization requests to Carelon Medical Benefits Management in one of several ways:

- Access the *ProviderPortal*<sup>SM</sup> directly at [www.providerportal.com](http://www.providerportal.com).
  - **Online access is available 24/7 to process orders in real-time and is the fastest and most convenient way to request authorization.**
- Access Carelon Medical Benefits Management via Availity Essentials\* at [www.availity.com](http://www.availity.com).

The Prior Authorization Lookup Tool allows providers to search codes by the specific line of business (Medicaid/SCHIP/Family Care, or Hoosier Care Connect) to determine if prior authorization (PA) is required and **which guideline is utilized for the case review**. The Prior Authorization Lookup Tool is available at <https://providers.anthem.com/in> > Claims > **Precertification lookup tool**.

<b>CPT<sup>®</sup> code</b>	<b>Description</b>	<b>Clinical UM Guideline title</b>
81206	BCR/ABL1 (t(9;22)) (such as chronic myelogenous leukemia) translocation analysis; major breakpoint, qualitative or quantitative	<a href="#">MCG: Acute Lymphoblastic Leukemia - BCR-ABL1 Fusion Gene Testing (A-0759)</a>  <a href="#">MCG: Chronic Myelogenous Leukemia - BCR-ABL1 Fusion Gene Testing (A-0771)</a>
81207	BCR/ABL1 (t(9;22)) (such as chronic myelogenous leukemia) translocation analysis; minor breakpoint, qualitative or quantitative	<a href="#">MCG: Acute Lymphoblastic Leukemia - BCR-ABL1 Fusion Gene Testing (A-0759)</a>  <a href="#">MCG: Chronic Myelogenous Leukemia - BCR-ABL1 Fusion Gene Testing (A-0771)</a>
81208	BCR/ABL1 (t(9;22)) (such as chronic myelogenous leukemia) translocation analysis; other breakpoint, qualitative or quantitative	<a href="#">MCG: Acute Lymphoblastic Leukemia - BCR-ABL1 Fusion Gene Testing (A-0759)</a>  <a href="#">MCG: Chronic Myelogenous Leukemia - BCR-ABL1 Fusion Gene Testing (A-0771)</a>

Carelon Medical Benefits Management is an independent company providing utilization review services on behalf of Anthem Blue Cross and Blue Shield. Availity, LLS is an independent company providing administrative support services on behalf of Anthem Blue Cross and Blue Shield.

### **<https://providers.anthem.com/in>**

Anthem Blue Cross and Blue Shield is the trade name of Anthem Insurance Companies, Inc., independent licensee of the Blue Cross and Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc.

Providers who are contracted with Anthem Blue Cross and Blue Shield to serve Hoosier Healthwise, Healthy Indiana Plan and Hoosier Care Connect through an accountable care organization (ACO), participating medical group (PMG) or Independent Physician Association (IPA) are to follow guidelines and practices of the group. This includes but is not limited to authorization, covered benefits and services, and claims submittal. If you have questions, please contact your group administrator or your Anthem network representative.

81218	CEBPA (CCAAT/enhancer binding protein [C/EBP], alpha) (such as acute myeloid leukemia), gene analysis, full gene sequence	Medicare (MCR): MolDX: Molecular Diagnostic Tests (MDT) (L36807)
81310	NPM1 (nucleophosmin) (such as acute myeloid leukemia) gene analysis, exon 12 variants	Medicare (MCR): MolDX: Molecular Diagnostic Tests (MDT) (L36807)  Medicare (MCR): MolDX: Minimal Residual Disease Testing for Cancer (L38835)
81315	PML/RARalpha, (t(15;17)), (promyelocytic leukemia/retinoic acid receptor alpha) (such as promyelocytic leukemia) translocation analysis; common breakpoints (such as intron 3 and intron 6), qualitative or quantitative	MCG: Acute Promyelocytic Leukemia - PML-RARA Fusion Gene Testing (A-0760)
81316	PML/RARalpha, (t(15;17)), (promyelocytic leukemia/retinoic acid receptor alpha) (such as promyelocytic leukemia) translocation analysis; single breakpoint (such as intron 3, intron 6 or exon 6), qualitative or quantitative	MCG: Acute Promyelocytic Leukemia - PML-RARA Fusion Gene Testing (A-0760)

If you have questions, Availability Chat with Payer is available during normal business hours. Get answers to your questions about eligibility, benefits, authorizations, claims status, and more. To access Availability Essentials, go to [availity.com](https://www.availity.com) and select the appropriate payer space tile from the drop-down. Then, select **Chat with Payer** and complete the pre-chat form to start your chat. Additionally, you may access and download a copy of the current and upcoming guidelines [here](#).

For additional support, visit the *Contact Us* section at the bottom of our provider website for the appropriate contact.